Mavacamten Controlled Hypertrophic Cardiomyopathy for >1 Year

Open-label mavacamten for a median of 62 weeks in patients with symptomatic obstructive hypertrophic cardiomyopathy showed ongoing safety and efficacy.
Medscape Medical News